LENZ (LENZ Therapeutics) Pre-Tax Income : $-49.77 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is LENZ Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. LENZ Therapeutics's pretax income for the three months ended in Dec. 2024 was $-12.65 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-49.77 Mil. LENZ Therapeutics's pretax margin was %.

During the past 4 years, LENZ Therapeutics's highest Pretax Margin was -69.76%. The lowest was -69.76%. And the median was -69.76%.

LENZ Therapeutics Pre-Tax Income Historical Data

The historical data trend for LENZ Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LENZ Therapeutics Pre-Tax Income Chart

LENZ Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Pre-Tax Income

-7.56

-10.46

-70.15

-49.77

LENZ Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial						-23.87	-16.65	-10.25	-10.22	-12.65

Competitive Comparison of LENZ Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, LENZ Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LENZ Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LENZ Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where LENZ Therapeutics's Pre-Tax Income falls into.

LENZ Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

LENZ Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-58.61	+	0.289	+	0	+	8.553	+	0
	=	-49.77

LENZ Therapeutics's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-15.225	+	0.008	+	0	+	2.566	+	0
	=	-12.65

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.77 Mil.

LENZ Therapeutics (NAS:LENZ) Pre-Tax Income Explanation

LENZ Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-12.651	/	0
	=	%

During the past 4 years, LENZ Therapeutics's highest Pretax Margin was -69.76%. The lowest was -69.76%. And the median was -69.76%.

LENZ Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of LENZ Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

LENZ Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LENZ Therapeutics Inc (NAS:LENZ) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

445 Marine View Avenue, STE No. 320, Del Mar, CA, USA, 92014

Website

https://www.lenz-tx.com

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.